---
document_datetime: 2025-12-02 05:05:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/arikayce-liposomal.html
document_name: arikayce-liposomal.html
version: success
processing_time: 0.1758009
conversion_datetime: 2025-12-26 18:08:09.536124
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Arikayce liposomal

[RSS](/en/individual-human-medicine.xml/67360)

##### Authorised

This medicine is authorised for use in the European Union

amikacin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Arikayce liposomal](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-77912)
- [More information on Arikayce liposomal](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Arikayce liposomal is an antibiotic for treating adults with a lung infection caused by *Mycobacterium avium* complex (MAC), a group of bacteria commonly found in the environment, such as in soil and water. It is used in patients with limited treatment options who do not have cystic fibrosis.

Lung infection caused by MAC is rare, and Arikayce liposomal was designated an 'orphan medicine' (a medicine used in rare diseases) on 8 April 2014.

Arikayce liposomal contains the active substance amikacin.

Expand section

Collapse section

## How is Arikayce liposomal used?

Amikacin is an antibiotic that belongs to the group 'aminoglycosides'. It works by disrupting the production of proteins that bacteria need to build their cell walls, thereby damaging the bacteria and eventually killing them. In this medicine, amikacin is contained in tiny fat particles known as liposomes, which allows the medicine to remain in the lung for longer.

## How does Arikayce liposomal work?

Amikacin is an antibiotic that belongs to the group 'aminoglycosides'. It works by disrupting the production of proteins that bacteria need to build their cell walls, thereby damaging the bacteria and eventually killing them. In this medicine, amikacin is contained in tiny fat particles known as liposomes, which allows the medicine to remain in the lung for longer.

## What benefits of Arikayce liposomal have been shown in studies?

A main study in 336 patients showed that Arikayce liposomal is effective at clearing lung infections caused by MAC. After 6 months of treatment, 29% of patients on standard care who used Arikayce liposomal tested negative for the infection, compared with 9% of patients on standard care alone. In addition, 3 months after stopping treatment, 55% of patients whose infections cleared with Arikayce liposomal continued to test negative. No patient who received standard care tested negative 3 months after stopping treatment.

## What are the risks associated with Arikayce liposomal?

The most common side effects with Arikayce liposomal affect the lungs and airways: dysphonia (changes to the voice), cough, dyspnoea (difficulty breathing) and haemoptysis (coughing up blood) may affect more than 1 person in 10.

Other common side effects include pain in the mouth or throat, tiredness, diarrhoea, worsening of bronchiectasis (weakened, scarred airways and build-up of mucus) due to infection, nausea (feeling sick) and bronchospasm.

Arikayce liposomal must not be used in patients who are hypersensitive (allergic) to soya, to any aminoglycoside antibiotic or to any ingredient of this medicine. It must also not be used together with another aminoglycoside or in patients with severely impaired kidneys.

For the full list of side effects of Arikayce liposomal, see the package leaflet.

## Why is Arikayce liposomal authorised in the EU?

The main study showed that Arikayce liposomal can clear MAC lung infection in some patients. Although the effect of Arikayce liposomal is modest, the medicine could benefit patients who have few treatment options. In terms of its safety, Arikayce liposomal can cause significant side effects, particularly during the first months of treatment. The Agency therefore recommended restricting the medicine to patients with limited treatment options.

The Agency concluded that the benefits of Arikayce liposomal outweigh its risks and that it can be authorised in the EU.

## What measures are being taken to ensure the safe and effective use of Arikayce liposomal?

The company will provide patients taking the medicine with an alert card to inform them of the risk of allergic alveolitis (inflammation in the lungs due to an allergy).

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Arikayce liposomal have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Arikayce liposomal are continuously monitored. Side effects reported with Arikayce liposomal are carefully evaluated and any necessary action taken to protect patients.

## Other information about Arikayce liposomal

Arikayce liposomal received a marketing authorisation valid throughout the EU on 27 October 2020.

Arikayce liposomal : EPAR - Medicine overview

Reference Number: EMA/446084/2020

English (EN) (123.44 KB - PDF)

**First published:** 18/11/2020

[View](/en/documents/overview/arikayce-liposomal-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-773)

български (BG) (148.8 KB - PDF)

**First published:**

18/11/2020

[View](/bg/documents/overview/arikayce-liposomal-epar-medicine-overview_bg.pdf)

español (ES) (125.25 KB - PDF)

**First published:**

18/11/2020

[View](/es/documents/overview/arikayce-liposomal-epar-medicine-overview_es.pdf)

čeština (CS) (146.4 KB - PDF)

**First published:**

18/11/2020

[View](/cs/documents/overview/arikayce-liposomal-epar-medicine-overview_cs.pdf)

dansk (DA) (123.55 KB - PDF)

**First published:**

18/11/2020

[View](/da/documents/overview/arikayce-liposomal-epar-medicine-overview_da.pdf)

Deutsch (DE) (116.52 KB - PDF)

**First published:**

18/11/2020

[View](/de/documents/overview/arikayce-liposomal-epar-medicine-overview_de.pdf)

eesti keel (ET) (122.69 KB - PDF)

**First published:**

18/11/2020

[View](/et/documents/overview/arikayce-liposomal-epar-medicine-overview_et.pdf)

ελληνικά (EL) (158.28 KB - PDF)

**First published:**

18/11/2020

[View](/el/documents/overview/arikayce-liposomal-epar-medicine-overview_el.pdf)

français (FR) (126.21 KB - PDF)

**First published:**

18/11/2020

[View](/fr/documents/overview/arikayce-liposomal-epar-medicine-overview_fr.pdf)

hrvatski (HR) (146.72 KB - PDF)

**First published:**

18/11/2020

[View](/hr/documents/overview/arikayce-liposomal-epar-medicine-overview_hr.pdf)

italiano (IT) (123.65 KB - PDF)

**First published:**

18/11/2020

[View](/it/documents/overview/arikayce-liposomal-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (163.5 KB - PDF)

**First published:**

18/11/2020

[View](/lv/documents/overview/arikayce-liposomal-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (147.29 KB - PDF)

**First published:**

18/11/2020

[View](/lt/documents/overview/arikayce-liposomal-epar-medicine-overview_lt.pdf)

magyar (HU) (147.02 KB - PDF)

**First published:**

18/11/2020

[View](/hu/documents/overview/arikayce-liposomal-epar-medicine-overview_hu.pdf)

Malti (MT) (156.58 KB - PDF)

**First published:**

18/11/2020

[View](/mt/documents/overview/arikayce-liposomal-epar-medicine-overview_mt.pdf)

Nederlands (NL) (124.33 KB - PDF)

**First published:**

18/11/2020

[View](/nl/documents/overview/arikayce-liposomal-epar-medicine-overview_nl.pdf)

polski (PL) (148.58 KB - PDF)

**First published:**

18/11/2020

[View](/pl/documents/overview/arikayce-liposomal-epar-medicine-overview_pl.pdf)

português (PT) (125.36 KB - PDF)

**First published:**

18/11/2020

[View](/pt/documents/overview/arikayce-liposomal-epar-medicine-overview_pt.pdf)

română (RO) (154.49 KB - PDF)

**First published:**

18/11/2020

[View](/ro/documents/overview/arikayce-liposomal-epar-medicine-overview_ro.pdf)

slovenčina (SK) (147.59 KB - PDF)

**First published:**

18/11/2020

[View](/sk/documents/overview/arikayce-liposomal-epar-medicine-overview_sk.pdf)

slovenščina (SL) (144.83 KB - PDF)

**First published:**

18/11/2020

[View](/sl/documents/overview/arikayce-liposomal-epar-medicine-overview_sl.pdf)

Suomi (FI) (122.95 KB - PDF)

**First published:**

18/11/2020

[View](/fi/documents/overview/arikayce-liposomal-epar-medicine-overview_fi.pdf)

svenska (SV) (123.61 KB - PDF)

**First published:**

18/11/2020

[View](/sv/documents/overview/arikayce-liposomal-epar-medicine-overview_sv.pdf)

Arikayce liposomal : EPAR - Risk management plan

English (EN) (675.42 KB - PDF)

**First published:** 18/11/2020

**Last updated:** 10/07/2025

[View](/en/documents/rmp/arikayce-liposomal-epar-risk-management-plan_en.pdf)

## Product information

Arikayce liposomal : Product information

English (EN) (250.01 KB - PDF)

**First published:** 18/11/2020

**Last updated:** 14/10/2025

[View](/en/documents/product-information/arikayce-liposomal-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-89)

български (BG) (385.16 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/bg/documents/product-information/arikayce-liposomal-product-information_bg.pdf)

español (ES) (280.61 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/es/documents/product-information/arikayce-liposomal-product-information_es.pdf)

čeština (CS) (376.46 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/cs/documents/product-information/arikayce-liposomal-product-information_cs.pdf)

dansk (DA) (248.96 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/da/documents/product-information/arikayce-liposomal-product-information_da.pdf)

Deutsch (DE) (268.28 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/de/documents/product-information/arikayce-liposomal-product-information_de.pdf)

eesti keel (ET) (246.91 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/et/documents/product-information/arikayce-liposomal-product-information_et.pdf)

ελληνικά (EL) (543.28 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/el/documents/product-information/arikayce-liposomal-product-information_el.pdf)

français (FR) (277.47 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/fr/documents/product-information/arikayce-liposomal-product-information_fr.pdf)

hrvatski (HR) (345.97 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/hr/documents/product-information/arikayce-liposomal-product-information_hr.pdf)

íslenska (IS) (258.25 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/is/documents/product-information/arikayce-liposomal-product-information_is.pdf)

italiano (IT) (246.37 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/it/documents/product-information/arikayce-liposomal-product-information_it.pdf)

latviešu valoda (LV) (367.1 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/lv/documents/product-information/arikayce-liposomal-product-information_lv.pdf)

lietuvių kalba (LT) (343.82 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/lt/documents/product-information/arikayce-liposomal-product-information_lt.pdf)

magyar (HU) (348.07 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/hu/documents/product-information/arikayce-liposomal-product-information_hu.pdf)

Malti (MT) (368.42 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/mt/documents/product-information/arikayce-liposomal-product-information_mt.pdf)

Nederlands (NL) (252.45 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/nl/documents/product-information/arikayce-liposomal-product-information_nl.pdf)

norsk (NO) (254.02 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/no/documents/product-information/arikayce-liposomal-product-information_no.pdf)

polski (PL) (361.21 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/pl/documents/product-information/arikayce-liposomal-product-information_pl.pdf)

português (PT) (250.97 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/pt/documents/product-information/arikayce-liposomal-product-information_pt.pdf)

română (RO) (348.68 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/ro/documents/product-information/arikayce-liposomal-product-information_ro.pdf)

slovenčina (SK) (354.79 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/sk/documents/product-information/arikayce-liposomal-product-information_sk.pdf)

slovenščina (SL) (344.34 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/sl/documents/product-information/arikayce-liposomal-product-information_sl.pdf)

Suomi (FI) (253.31 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/fi/documents/product-information/arikayce-liposomal-product-information_fi.pdf)

svenska (SV) (245.97 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

14/10/2025

[View](/sv/documents/product-information/arikayce-liposomal-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000284843 18/09/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Arikayce liposomal : EPAR - All authorised presentations

English (EN) (46.9 KB - PDF)

**First published:** 18/11/2020

[View](/en/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-71)

български (BG) (56.99 KB - PDF)

**First published:**

18/11/2020

[View](/bg/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_bg.pdf)

español (ES) (48.19 KB - PDF)

**First published:**

18/11/2020

[View](/es/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_es.pdf)

čeština (CS) (54.27 KB - PDF)

**First published:**

18/11/2020

[View](/cs/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (48.79 KB - PDF)

**First published:**

18/11/2020

[View](/da/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (49.46 KB - PDF)

**First published:**

18/11/2020

[View](/de/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (47.88 KB - PDF)

**First published:**

18/11/2020

[View](/et/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (60.18 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

10/07/2025

[View](/el/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_el.pdf)

français (FR) (45.54 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

10/07/2025

[View](/fr/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (66.19 KB - PDF)

**First published:**

18/11/2020

[View](/hr/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (47.93 KB - PDF)

**First published:**

18/11/2020

[View](/is/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_is.pdf)

italiano (IT) (47.19 KB - PDF)

**First published:**

18/11/2020

[View](/it/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (64.15 KB - PDF)

**First published:**

18/11/2020

[View](/lv/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (540.38 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

10/07/2025

[View](/lt/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (54.73 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

10/07/2025

[View](/hu/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (68.09 KB - PDF)

**First published:**

18/11/2020

[View](/mt/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (45.1 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

10/07/2025

[View](/nl/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (48.66 KB - PDF)

**First published:**

18/11/2020

[View](/no/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_no.pdf)

polski (PL) (67.89 KB - PDF)

**First published:**

18/11/2020

[View](/pl/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_pl.pdf)

português (PT) (49.07 KB - PDF)

**First published:**

18/11/2020

[View](/pt/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_pt.pdf)

română (RO) (62.17 KB - PDF)

**First published:**

18/11/2020

[View](/ro/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (64.49 KB - PDF)

**First published:**

18/11/2020

[View](/sk/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (53.13 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

10/07/2025

[View](/sl/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (46.74 KB - PDF)

**First published:**

18/11/2020

[View](/fi/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (45.02 KB - PDF)

**First published:**

18/11/2020

**Last updated:**

10/07/2025

[View](/sv/documents/all-authorised-presentations/arikayce-liposomal-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Arikayce liposomal Active substance amikacin sulfate International non-proprietary name (INN) or common name amikacin Therapeutic area (MeSH) Respiratory Tract Infections Anatomical therapeutic chemical (ATC) code J01GB06

### Pharmacotherapeutic group

Antibacterials for systemic use

### Therapeutic indication

Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by *Mycobacterium avium* Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.

## Authorisation details

EMA product number EMEA/H/C/005264

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

Marketing authorisation holder

Insmed Netherlands B.V.

Stadsplateau 7

Opinion adopted 23/07/2020 Marketing authorisation issued 27/10/2020 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Arikayce liposomal : Procedural steps taken and scientific information after authorisation

English (EN) (143.36 KB - PDF)

**First published:** 14/10/2025

[View](/en/documents/procedural-steps-after/arikayce-liposomal-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Arikayce liposomal : Procedural steps taken and scientific information after authorisation (archive)

English (EN) (160.91 KB - PDF)

**First published:** 09/11/2021

**Last updated:** 10/07/2025

[View](/en/documents/procedural-steps-after/arikayce-liposomal-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Arikayce liposomal-H-C-PSUSA-00010882-202209 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/155354/2023

English (EN) (97.18 KB - PDF)

**First published:** 04/08/2023

[View](/en/documents/scientific-conclusion/arikayce-liposomal-h-c-psusa-00010882-202209-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Arikayce liposomal : Orphan designation assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-518626

English (EN) (346 KB - PDF)

**First published:** 18/11/2020

[View](/en/documents/orphan-maintenance-report/arikayce-liposomal-orphan-designation-assessment-report-initial-authorisation_en.pdf)

Arikayce liposomal : EPAR - Public assessment report

Adopted

Reference Number: EMA/473660/2020

English (EN) (4.82 MB - PDF)

**First published:** 18/11/2020

[View](/en/documents/assessment-report/arikayce-liposomal-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Arikayce liposomal

Adopted

Reference Number: EMA/CHMP/257409/2020 Corr.

English (EN) (132.25 KB - PDF)

**First published:** 24/07/2020

**Last updated:** 28/07/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-arikayce-liposomal_en.pdf)

#### News on Arikayce liposomal

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020) 24/07/2020

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Arikayce liposomal : EPAR - Product information - tracked changes

English (EN) (289.31 KB - DOCX)

**First published:** 10/07/2025

[View](/en/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-407)

български (BG) (328.2 KB - DOCX)

**First published:**

10/07/2025

[View](/bg/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_bg.docx)

español (ES) (312.67 KB - DOCX)

**First published:**

10/07/2025

[View](/es/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_es.docx)

čeština (CS) (326.12 KB - DOCX)

**First published:**

10/07/2025

[View](/cs/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (326.4 KB - DOCX)

**First published:**

10/07/2025

[View](/da/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (324.44 KB - DOCX)

**First published:**

10/07/2025

[View](/de/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (437 KB - DOC)

**First published:**

10/07/2025

[View](/et/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_et.doc)

ελληνικά (EL) (295.29 KB - DOCX)

**First published:**

10/07/2025

[View](/el/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_el.docx)

français (FR) (315.46 KB - DOCX)

**First published:**

10/07/2025

[View](/fr/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (314.33 KB - DOCX)

**First published:**

10/07/2025

[View](/hr/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (323.45 KB - DOCX)

**First published:**

10/07/2025

[View](/is/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_is.docx)

italiano (IT) (319.01 KB - DOCX)

**First published:**

10/07/2025

[View](/it/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (315.85 KB - DOCX)

**First published:**

10/07/2025

[View](/lv/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (310.23 KB - DOCX)

**First published:**

10/07/2025

[View](/lt/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (503 KB - DOC)

**First published:**

10/07/2025

[View](/hu/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_hu.doc)

Malti (MT) (311.58 KB - DOCX)

**First published:**

10/07/2025

[View](/mt/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (312.41 KB - DOCX)

**First published:**

10/07/2025

[View](/nl/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (305.53 KB - DOCX)

**First published:**

10/07/2025

[View](/no/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_no.docx)

polski (PL) (308.53 KB - DOCX)

**First published:**

10/07/2025

[View](/pl/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_pl.docx)

português (PT) (294.66 KB - DOCX)

**First published:**

10/07/2025

[View](/pt/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_pt.docx)

română (RO) (494 KB - DOC)

**First published:**

10/07/2025

[View](/ro/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_ro.doc)

slovenčina (SK) (312.25 KB - DOCX)

**First published:**

10/07/2025

[View](/sk/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (306.16 KB - DOCX)

**First published:**

10/07/2025

[View](/sl/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (308.12 KB - DOCX)

**First published:**

10/07/2025

[View](/fi/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (304.77 KB - DOCX)

**First published:**

10/07/2025

[View](/sv/documents/product-information-tracked-changes/arikayce-liposomal-epar-product-information-tracked-changes_sv.docx)

#### More information on Arikayce liposomal

- [EMEA-000525-PIP01-08-M08 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000525-pip01-08-m08)
- [EU/3/14/1259 - orphan designation for treatment of nontuberculous mycobacterial lung disease](/en/medicines/human/orphan-designations/eu-3-14-1259)

**This page was last updated on** 14/10/2025

## Share this page

[Back to top](#main-content)